Posts filtered by tags: Eisai[x]


 

Alzheimer's nasal vaccine to enter human trials for the first time, spurring renewed hope for preventing the disease

A laboratory worker tests a nasal spray (not related to Alzheimer's) at the Pharma and Beauty factory in Saint-Chamas, France, on January 21, 2021.Nicolas Tucat/AFP/Getty Images Brigham and Women's Hospital is spearheading the first human trial of an Alzheimer's nasal vaccine. The vaccine is designed to prevent or slow the progression of the disease. It uses a drug, Protollin, to stimulate immune cells to remove sticky plaque from the brain. Alzheimer's treatments seemed like ...
Tags: Science, News, Drugs, US, Trends, Alzheimer's Disease, Food And Drug Administration, Fda, Vaccines, Eisai, Cummings, Brigham, Alzheimer, University of Nevada Las Vegas, William Burke, Biogen


Fitness ring maker Oura raises $100M

It’s been a wild couple of years for Oura. Last year, in particular, proved to be a major driver for the wearable fitness manufacturer. With the pandemic bringing professional sports to a screeching halt in 2020, a number of major leagues have adopted the ring, including the NBA, WNBA, UFC and NASCAR. The company has also been making a major push into health research courtesy of UCSF, which has published peer-review studies around the ring’s temperature monitor. That feature in particular has ma...
Tags: Health, Startups, Wearables, Hardware, Fitness, Funding, Tech, Nascar, UCSF, Eisai, Chernin Group, Elysian Park, The Chernin Group, OURA, Eurie Kim, Tommi Heinonen


The FDA is delaying a controversial Alzheimer's drug decision. Analysts say that's a good sign.

Atthapon Raksthaput/Shutterstock The FDA is currently examining a Alzheimer's disease drug developed by Biogen and Eisai. Outside experts have said data from two halted trials don't prove the drug is effective. Regulators pushed back the decision deadline to June 7, at latest. Visit Business Insider's homepage for more stories. The Food and Drug Administration is delaying its decision deadline for Biogen and Eisai's hotly debated Alzheimer's disease drug, a move that analysts said bodes w...
Tags: Science, Trends, Alzheimer's Disease, Healthcare, Food And Drug Administration, Fda, Jefferies, Providence, Eisai, Biogen, Aducanumab, Michael Yee, Butler Hospital, Charles Krupa Associated Press, Brian Skorney, Dispensed


Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug

As the Alzheimer’s disease world continues to closely follow the development of therapies that break up clumps of beta amyloid on patients’ brains, Roche is placing a bet on another approach via a deal that secures rights to a clinical-stage UCB compound that targets tau, another protein associated with the neurodegenerative disorder.According to terms announced Wednesday, Roche is paying $120 million up front for global rights to the UCB drug, UCB0107. Belgium-based UCB remains responsible for...
Tags: Deals, Europe, Trends, Neuroscience, Alzheimer's Disease, Belgium, Biotech, Life Sciences, Genentech, UCB, Roche, Eisai, Biogen, Eli Lilly, Tau, National blog main


Guide to Japanese green teas

In Timothy d’Offay’s book The Life of Tea, which he co-authored with Michael Freeman, d’Offay characterizes Japan’s love of green tea as a “near-obsession.” Well, that’s almost true. Japanese people actually drink more coffee than tea, according to Hiroshi Nishikawa, assistant director of the Tea Industry Development sector of Shizuoka prefecture’s local government. That certainly doesn’t mean tea is going out of style, though. Data from 2013 suggests that the average Japanese person drinks ...
Tags: Travel, Tea, Asia, Japan, China, Green Tea, Kyoto, All, Tokushima, Shizuoka, Kyushu, Eisai, Japanese green tea, Bancha, Nishikawa, Kyushu Island


Weight Loss Drug Belviq Pulled From Market Over ‘Slight’ Cancer Risk

The maker of a weight loss drug pulled it from the market Thursday at the request of federal regulators, who said it posed a slight increased risk of cancer. Japan’s Eisai Inc. said it was voluntarily withdrawing the drug, Belviq. (The company’s U.S. headquarters is in Woodcliff Lake, New Jersey.) However, the company said in a statement that it disagreed with the U.S. Food and Drug Administration’s interpretation of new data on the drug’s safety and still believes Belviq’s benefit outweigh...
Tags: Japan, News, Uncategorized, Fda, U S Food and Drug Administration, Eisai, Eisai Inc, Belviq, Onetime, Woodcliff Lake New Jersey, Belviq Contrave


Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More

Drugs typically go through three phases of clinical testing to support an application for FDA approval. It’s easy to overlook Phase 4, which takes place after a drug reaches the market.Post-marketing studies aim to identify side effects not observed in the first three phases of testing. They also evaluate how a therapy works over a longer period of time. This week, results of such a study led to the market withdrawal of weight-loss pill lorcaserin (Belviq). When the FDA approved the drug in 201...
Tags: Deals, Startups, Post, Ipo, Cancer, Trends, Investing, Merck, Alzheimer's Disease, Fda, National, Novartis, Pfizer, Biotech, Cystic Fibrosis, Theranos


Drugmaker Eisai to withdraw weight loss drug Belviq after trials find cancer link

Eisai Co. will withdraw its weight loss drug Belviq after the US Food and Drug Administration said clinical trials showed an increased incidence of cancer among users, the company said.
Tags: Health, US Food and Drug Administration, Eisai, Eisai Co


Drugmaker Eisai to withdraw weight loss drug Belviq after trials find cancer link

Eisai Co. will withdraw its weight loss drug Belviq after the US Food and Drug Administration said clinical trials showed an increased incidence of cancer among users, the company said.
Tags: Cnn, US Food and Drug Administration, Eisai, Eisai Co


Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More

In the week leading up to Christmas, six drugs won FDA approvals. The decisions covered insomnia, migraine, and several different forms of cancer.The FDA’s final tally for the year totaled 48 new drug approvals. If you’re keeping score, that compares with 59 approvals in 2018 and 46 in 2017. Most of the nods went to small molecule drugs and cancer drugs continued to represent a significant chunk of the new approved medicines. For what it’s worth, the FDA didn’t say how many drugs it rejected in...
Tags: Deals, Startups, Breast Cancer, Cancer, Trends, Investing, Merck, Anemia, Schizophrenia, Astrazeneca, Fda, National, Pfizer, Allergan, Biotech, Pancreatic Cancer


Chanoyu: History and Philosophy – Part 1

In recent articles (Chanoyu, Temae, and Chadogu and Essential Low-Ranking Chadogu for Ceremony of Tea), I mentioned the traditional green tea ceremony, called “Chanoyu” and “The Way of Tea”.  Since those blogs, many of you have asked that I explain it in a bit more detail. I’m thrilled to do so. The Japanese tea ceremony is a topic that is very dear to me.  The tea ceremony comes from centuries of tea school teachings ...
Tags: Tea, Japan, China, Kyoto, Zen Buddhism, Jo, Eisai, Chanoyu, Shuko, Generic License, Chadogu, Murata Shuko, Zen Takeno Jo, Donna Cleveland


Eisai transfers rights to Royalty Pharma to receive royalties on net sales of tazemetostat drug

Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.
Tags: Health, Japan, Eisai, Eisai Co Ltd, Royalty Pharma


Eisai transfers rights to Royalty Pharma relating to net sales of EZH2 inhibitor outside of Japan

Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.
Tags: Health, Japan, Eisai, Eisai Co Ltd, Royalty Pharma


Drugmaker reverses course, plans to seek FDA approval for Alzheimer's treatment

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for the drug aducanumab, an experimental treatment for early Alzheimer's disease, Biogen and its Japanese partner Eisai announced on Tuesday.
Tags: Cnn, Fda, US Food and Drug Administration, Eisai, Biogen


TRIA to design dementia discovery center for Eisai

Cambridge, MA TRIA has been selected by Eisai Inc. to design its Center for Genetics Guided Dementia Discovery (G2D...
Tags: Radio, Eisai, Eisai Inc, TRIA, Cambridge MA TRIA


Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More

America continues to suffer from healthcare headaches. Our convoluted private-public insurance system was under scrutiny this week from Democrats, holding a “Medicare for All” hearing in the House, and from Republicans, as several GOP-led states and the Trump administration asked a federal court to sweep away Obamacare.Several companies also want to reduce headaches. This week Xconomy previewed a flood of neurology data, much of it dedicated to migraine treatments—an increasingly crowded field....
Tags: Productivity, Board of Directors, Obamacare, Republicans, Hiv, America, Trends, Data, Vc, Democrats, Gop, House, Incubator, House Of Representatives, Studies, Rejection


Bill Gates says there could be a way to predict Alzheimer’s using a voice app that listens for 'warning signs'

Scientists have yet to find a cure for Alzheimer's, a disease whose symptoms include memory loss, impaired judgment, and difficulty speaking. About 14 million Americans are expected to be living with Alzheimer's by 2050. Doctors rely mostly on physical symptoms to diagnose the disease, though they can also use  spinal taps and brain scans to detect it. But Bill Gates envisions a future in which people can predict Alzheimer's before symptoms manifest using a voice app on their phones.  The roa...
Tags: Amazon, Massachusetts, Trends, Bill Gates, Jeff Bezos, Gates, Big Pharma, Eisai, Alzheimer, Biogen, National Institute, Diagnostics Accelerator, Laura Boylan


Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More

A week after , the ripple effects are still being felt—and not just by Biogen, which lost billions of dollars in market value in a flash.We’ll kick off this week’s roundup with the aducanumab reaction, which includes plenty of thoughts about the future of the so-called “amyloid hypothesis” and what’s next for another Biogen Alzheimer’s drug that has had mixed results.We’ll also check in on the gene therapy deal spree, the big week in national healthcare policy, and the preparations several com...
Tags: Deals, Obamacare, Trends, Alzheimer's Disease, Affordable Care Act, National, Pfizer, Medicaid, Xarelto, Federal Trade Commission, Life Sciences, Bayer, Clinical Trials, Celgene, Gilead Sciences, Eisai


Cerveau announces research collaboration agreement with Eisai for novel tau imaging agent

Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau's [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography scans to assess the status and progression of neurofibrillary tangles in the brain.
Tags: Health, Eisai, Eisai Inc, Cerveau, Cerveau Technologies Inc


Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab. On Friday, Eisai was untraded, flooded with sell orders at 7,565 yen, almost 17 percent lower than its previous close. The demise of aducanumab came after independent experts determined the trials had little hope of succeeding, marking the latest setback in the quest to treat ...
Tags: Science, United States, Eisai, Biogen Inc, Eisai Co Ltd


Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.
Tags: Money, businessNews, Eisai, Biogen Inc, Eisai Co Ltd


Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials

Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab.
Tags: Japan, Money, businessNews, Eisai, Biogen Inc, Eisai Co Ltd


Shares of Japan's Eisai swamped with sell orders after ending Alzheimer trials

Eisai Co Ltd's shares were untraded on Friday, hit with a glut of sell orders after the Japanese drugmaker and its partner Biogen Inc said they are ending two drug trials of their experimental Alzheimer's disease drug aducanumab. The decision, which wiped $18 billion off the value on Biogen on Thursday, marks a major setback in the quest to find a treatment for the mind-wasting disease and came after experts determined the trials had little hope of succeeding. Japanese markets were closed for...
Tags: Japan, Science, Eisai, Biogen Inc, Biogen, Eisai Co Ltd


Another promising Alzheimer's drug trial ends in failure: 'This one hurts'

Another Alzheimer's drug trial ends in failure. Pharmaceutical giant Biogen and its Japanese partner Eisai announced Thursday they were halting phase three clinical trials of aducanumab, a drug that targets the buildup in the brain of proteins that contribute to the development of Alzheimer's.
Tags: Cnn, Eisai, Biogen


Biogen shares plummet after ending potentially groundbreaking Alzheimer's drug trial

Biogen’s shares plummeted on Thursday after the biotechnology group announced it had ended a highly anticipated trial of Alzheimer’s drug aducanumab. The company, which was working alongside Japan’s pharmaceutical company Eisai on the phase III-trial to study treatment for patients with Alzheimer’s, said the decision was based on an independent group’s analysis. According to the analysis, the trials were not likely to “meet their primary endpoint”.
Tags: Japan, Science, Eisai, Biogen


Biogen Shares Plunge After Alzheimer’s Drug Setback

The Cambridge, Massachusetts-based company and partner Eisai Co. said Thursday that they would discontinue two late-stage trials designed to evaluate the efficacy and safety of the drug, aducanumab. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience,” said Michel Vounatsos, Biogen’s chief executive officer. Biogen is still studying other, earlier-stage compounds, and is continuing to work with Eisai on two ...
Tags: Science, Eisai, Cambridge Massachusetts, Biogen, Eisai Co, David Caouette, Michel Vounatsos Biogen


Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in Brazil to Eurofarma Laboratorios S.A. Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.
Tags: Health, Brazil, Eisai, Eisai Co Ltd


Eli Lilly Partners with AC Immune on Tau Blockers for Alzheimer’s

There’s at least one major pharmaceutical company that isn’t giving up yet on finding a drug for Alzheimer’s disease, despite a long trail of clinical flops. Eli Lilly is pairing up with AC Immune to develop drugs that block tau, a protein linked to the neurodegenerative disease.Under the agreement announced Wednesday, AC Immune (NASDAQ: ACIU) will receive from Lilly about $80 million up front, plus $50 million in the form of a convertible note, a form of debt financing that converts into equit...
Tags: Deals, Trends, Indiana, Alzheimer's Disease, Alzheimer's, Biotech, Partnership, Life Sciences, Eisai, Lilly, Biogen, Eli Lilly, Tau, National blog main, Boston blog main, Boston top stories


New collaborative partnership in quest of novel antibiotics

The Global Antibiotic Research and Development Partnership, Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited have signed an agreement for GARDP to access and screen components of Eisai and Takeda's chemical libraries.
Tags: Health, Eisai, Takeda, Takeda Pharmaceutical Company Limited


Arena’s Comeback Continues with $800M Deal for Lung Disease Drug

[Updated, 11/15/18, 2:06 p.m. ET. See below.] Arena Pharmaceuticals continued its comeback Thursday, netting a whopping $800 million up front in a deal that hands United Therapeutics another experimental drug for the rare disorder pulmonary arterial hypertension (PAH).The deal gives United Therapeutics (NASDAQ: UTHR) worldwide rights to Arena’s (NASDAQ: ARNA) experimental drug ralinepag, which is in late-stage testing for PAH. Aside from the massive upfront payment, the company, which splits it...
Tags: Deals, Trends, Ulcerative Colitis, San Diego, Fda, Biotech, Life Sciences, Clinical Trials, Arena, Arena Pharmaceuticals, Eisai, Silver Spring MD, United Therapeutics, Crohn's Disease, National blog main, National top stories